NCT05224609View on ClinicalTrials.gov

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

August 13, 2024

Study Completion Date

August 13, 2024

Conditions
Moderate Hepatic ImpairmentSevere Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

Lorlatinib

Single 100mg oral dose anti-cancer agent

Trial Locations (3)

33603

Genesis Clinical Research, LLC, Tampa

55114

Prism Research LLC dba Nucleus Network, Saint Paul

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05224609 - A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction | Biotech Hunter | Biotech Hunter